Overview

Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer

Status:
Not yet recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Fujian Cancer Hospital
Treatments:
Irinotecan